Georgian biopharmaceutical company BioChimPharm (BCP) has completed the modernisation of its historic Bacteriophage (Phage) manufacturing factory – a two-year investment project worth €6 million and implemented with support from the EU, the EBRD, FAO and the Ministry of Economy and Sustainable Development of Georgia.

As a result, BioChimPharm has converted the plant to comply with EU GMP (Good Manufacturing Practice) guidelines, an accepted standard in the European Union. The company also plans to apply for GMP certification in the coming months.

“The production of phage preparations and the phage therapy are still a novelty for most of the countries around the world. Millions of people still do not have access to phages, leaving patients vulnerable towards antibiotic-resistant infections,” explained Rati Golijashvili, GM, BioChimPharm. “With this project, the company is increasing its production capacity and export area, thus making phages available for millions of patients across the globe.”